Glaxosmithkline Plc Stock Operating Margin
| GSK Stock | 1,340 3.50 0.26% |
GlaxoSmithKline PLC fundamentals help investors to digest information that contributes to GlaxoSmithKline PLC's financial success or failures. It also enables traders to predict the movement of GlaxoSmithKline Stock. The fundamental analysis module provides a way to measure GlaxoSmithKline PLC's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to GlaxoSmithKline PLC stock.
GlaxoSmithKline | Operating Margin |
GlaxoSmithKline PLC Company Operating Margin Analysis
GlaxoSmithKline PLC's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current GlaxoSmithKline PLC Operating Margin | 0.08 % |
Most of GlaxoSmithKline PLC's fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, GlaxoSmithKline PLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Based on the recorded statements, GlaxoSmithKline PLC has an Operating Margin of 0.0833%. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The operating margin for all United Kingdom stocks is notably lower than that of the firm.
GlaxoSmithKline Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses GlaxoSmithKline PLC's direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of GlaxoSmithKline PLC could also be used in its relative valuation, which is a method of valuing GlaxoSmithKline PLC by comparing valuation metrics of similar companies.GlaxoSmithKline PLC is currently under evaluation in operating margin category among its peers.
GlaxoSmithKline PLC ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, GlaxoSmithKline PLC's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to GlaxoSmithKline PLC's managers, analysts, and investors.Environment Score | Governance Score | Social Score |
GlaxoSmithKline Fundamentals
| Return On Equity | 0.22 | ||||
| Return On Asset | 0.0724 | ||||
| Profit Margin | 0.08 % | ||||
| Operating Margin | 0.08 % | ||||
| Current Valuation | 67.69 B | ||||
| Shares Outstanding | 4.08 B | ||||
| Shares Owned By Insiders | 1.61 % | ||||
| Shares Owned By Institutions | 45.15 % | ||||
| Price To Book | 3.92 X | ||||
| Price To Sales | 1.75 X | ||||
| Revenue | 30.33 B | ||||
| Gross Profit | 19.92 B | ||||
| EBITDA | 9.14 B | ||||
| Net Income | 4.93 B | ||||
| Total Debt | 18.02 B | ||||
| Book Value Per Share | 3.43 X | ||||
| Cash Flow From Operations | 6.77 B | ||||
| Earnings Per Share | 0.61 X | ||||
| Price To Earnings To Growth | 0.76 X | ||||
| Target Price | 2128.25 | ||||
| Number Of Employees | 70.21 K | ||||
| Beta | 0.33 | ||||
| Market Capitalization | 54.7 B | ||||
| Total Asset | 59.01 B | ||||
| Retained Earnings | 7.24 B | ||||
| Working Capital | (2.42 B) | ||||
| Annual Yield | 0.04 % | ||||
| Net Asset | 59.01 B | ||||
| Last Dividend Paid | 0.61 |
About GlaxoSmithKline PLC Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze GlaxoSmithKline PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GlaxoSmithKline PLC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GlaxoSmithKline PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in GlaxoSmithKline Stock
GlaxoSmithKline PLC financial ratios help investors to determine whether GlaxoSmithKline Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in GlaxoSmithKline with respect to the benefits of owning GlaxoSmithKline PLC security.